Kynurenine pathway

The kynurenine pathway

The kynurenine pathway is a metabolic pathway leading to the production of nicotinamide adenine dinucleotide (NAD+).[1] Metabolites involved in the kynurenine pathway include tryptophan, kynurenine, kynurenic acid, xanthurenic acid, quinolinic acid, and 3-hydroxykynurenine.[2][3] The kynurenine pathway is responsible for about 95% of total tryptophan catabolism.[4] Disruption in the pathway is associated with certain genetic and psychiatric disorders.[5][2][6][7][8]

  1. ^ Bartoli, F; Cioni, RM; Cavaleri, D; Callovini, T; Crocamo, C; Misiak, B; Savitz, JB; Carrà, G (11 November 2022). "The association of kynurenine pathway metabolites with symptom severity and clinical features of bipolar disorder: An overview". European Psychiatry. 65 (1): e82. doi:10.1192/j.eurpsy.2022.2340. PMC 9724221. PMID 36366795.
  2. ^ a b Bartoli, F; Misiak, B; Callovini, T; Cavaleri, D; Cioni, RM; Crocamo, C; Savitz, JB; Carrà, G (July 2021). "The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites". Molecular Psychiatry. 26 (7): 3419–3429. doi:10.1038/s41380-020-00913-1. PMID 33077852. S2CID 224314102.
  3. ^ Savitz, J (25 January 2020). "The kynurenine pathway: a finger in every pie". Molecular Psychiatry. 25 (1): 131–147. doi:10.1038/s41380-019-0414-4. PMC 6790159. PMID 30980044.
  4. ^ Thomas, Sunil; Laury-Kleintop, Lisa; Prendergast, George C. (2019-01-01), "Chapter Twelve - Reliable detection of indoleamine 2,3 dioxygenase-1 in murine cells and tissues", in Galluzzi, Lorenzo; Rudqvist, Nils-Petter (eds.), Tumor Immunology and Immunotherapy – Molecular Methods, Methods in Enzymology, vol. 629, Academic Press, pp. 219–233, doi:10.1016/bs.mie.2019.08.008, PMID 31727242, S2CID 208037565, retrieved 2022-04-12
  5. ^ Marx, Wolfgang; McGuinness, Amelia J.; Rocks, Tetyana; Ruusunen, Anu; Cleminson, Jasmine; Walker, Adam J.; Gomes-da-Costa, Susana; Lane, Melissa; Sanches, Marsal; Diaz, Alexandre P.; Tseng, Ping-Tao (August 2021). "The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies". Molecular Psychiatry. 26 (8): 4158–4178. doi:10.1038/s41380-020-00951-9. ISSN 1359-4184. PMID 33230205. S2CID 227132820.
  6. ^ Bartoli, F; Cioni, RM; Callovini, T; Cavaleri, D; Crocamo, C; Carrà, G (17 May 2021). "The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites". Schizophrenia Research. 232: 61–62. doi:10.1016/j.schres.2021.04.008. PMID 34015557. S2CID 235074432.
  7. ^ Morrens, Manuel; De Picker, Livia; Kampen, Jarl K.; Coppens, Violette (September 2020). "Blood-based kynurenine pathway alterations in schizophrenia spectrum disorders: A meta-analysis". Schizophrenia Research. 223: 43–52. doi:10.1016/j.schres.2020.09.007. ISSN 1573-2509. PMID 32981827. S2CID 221883723.
  8. ^ Arnone, Danilo; Saraykar, Smita; Salem, Haitham; Teixeira, Antonio L.; Dantzer, Robert; Selvaraj, Sudhakar (September 2018). "Role of Kynurenine pathway and its metabolites in mood disorders: A systematic review and meta-analysis of clinical studies". Neuroscience and Biobehavioral Reviews. 92: 477–485. doi:10.1016/j.neubiorev.2018.05.031. ISSN 1873-7528. PMC 6686193. PMID 29940237.